Showing all 12 resultsSorted by popularity
Retatrutide (LY-3437943) is a first-in-class triple hormone agonist that simultaneously activates GLP-1, GIP, and glucagon receptors to drive extensive metabolic remodeling. It enhances insulin secretion, suppresses appetite, and boosts hepatic lipid oxidation for advanced weight loss research.
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.
The data from the trials mentioned that Retatrutide is effective in reducing weight in individuals with nonsyndromic obesity.
5mg *10 vials *1 kits
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.
The data from the trials mentioned that Retatrutide is effective in reducing weight in individuals with nonsyndromic obesity.
5mg *10 vials *1 kits
Dual GLP-1/GIP receptor agonist for weight management and metabolic research. Study incretin signaling and glucose regulation.
Min order >20 kits price low to $350/kit
Min order >20 kits price low to $260/kit
Min order >20 kits price low to $185/kit
Min order >20 kits price low to $135/kit
Min order >20 kits price low to $95/kit
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.
The data from the trials mentioned that Retatrutide is effective in reducing weight in individuals with nonsyndromic obesity.
5mg *10 vials *1 kits
Retatrutide (LY-3437943) is a first-in-class triple hormone agonist that simultaneously activates GLP-1, GIP, and glucagon receptors to drive extensive metabolic remodeling. It enhances insulin secretion, suppresses appetite, and boosts hepatic lipid oxidation for advanced weight loss research.
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.
The data from the trials mentioned that Retatrutide is effective in reducing weight in individuals with nonsyndromic obesity.
5mg *10 vials *1 kits
End of content
End of content
No products in the cart.
